MAGE-1.A2

MAGE-1.A2 is an investigational peptide-based cancer vaccine developed by the Ludwig Institute for Cancer Research. It consists of a synthetic peptide derived from the MAGE-1 (Melanoma Antigen Gene 1) protein, specifically an epitope restricted to the HLA-A2 MHC class I allele. MAGE-1 is a cancer/testis antigen expressed in various tumors, including melanoma, but absent in normal adult tissues except the testis. The vaccine is designed to stimulate cytotoxic T-lymphocyte (CTL) responses against MAGE-1-expressing tumor cells in HLA-A2-positive patients. In clinical studies, it has been evaluated in combination with adjuvants like CpG 7909 for the treatment of metastatic melanoma.

Other names

MAGE-1 peptideMAGE1 peptideMAGE 1 peptideMAGE-1 HLA-A2 peptideMAGE1 HLA-A2 peptideMAGE 1 HLA-A2 peptideMAGE-1(161-169) peptide